RetiNext

The company will continue the development of a molecule to contrast Retinal pathologies based on excitotoxicity

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Milan, Metropolitan City of Milan, Italy
  • Currency EUR
  • Founded February 2016
  • Employees 3

Company Summary

The company will be a classical biotechnology company.
1st round:
- extend patent in international countries.
- perform specific pathology model experiments
- molecule production tests
- seeking for new funds
2nd round allows to reach clinical phase I within 2,5 years.
At the beginning of Clinical Phase I we will search for new finance from specialized Venture Capitals.
Co-development for different pathologies (not EYE) with big pharma

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free